CA Patent

CA3215903A1 — Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent

Assigned to Incyte Corp · Expires 2022-10-20 · 4y expired

What this patent protects

The present disclosure relates to methods of treating cancer by administering a compound, which is an Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with enfortumab vedotin.

USPTO Abstract

The present disclosure relates to methods of treating cancer by administering a compound, which is an Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with enfortumab vedotin.

Drugs covered by this patent

Patent Metadata

Patent number
CA3215903A1
Jurisdiction
CA
Classification
—
Expires
2022-10-20
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.